BioWorld: “Report on American Gene Technologies’s Progress Toward an HIV Cure”

American Gene Technologies International Inc. (AGT), of Rockville, Md., disclosed completion of the pilot runs of its HIV cure automated cell processing protocol. That completes a key milestone of the firm’s planned phase I trial of AGT103-T, a genetically modified autologous T-cell product in development as an HIV cure. The company has produced a GMP-grade lentiviral vector stock that will modify HIV-specific T cells to make them immune to HIV entry and depletion, having fully developed the process for treating cells, in an automated unit, which reliably manufactures the cell product, AGT said.